Central European Cooperative Oncology Group   Report issue

Government Phase 1 Phase 2 Phase 3
Founded: Vienna Austria (1999)

Organization Overview

First Clinical Trial
2001
NCT00022191
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Renal Cell (Phase 3)

Carcinoma, Transitional Cell (Phase 3)

Colorectal Neoplasms (Phase 2)

Gastrointestinal Stromal Tumors (Phase 3)

Kidney Neoplasms (Phase 3)

Lung Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 3)

Prostatic Neoplasms (Phase 3)

Ureteral Neoplasms (Phase 3)

Urethral Neoplasms (Phase 3)

Urinary Bladder Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 14
  • # of Trial APIs: 22